Novo Nordisk executives overlooked warnings ahead of Wegovy’s launch, leading to supply issues, high costs, and challenges competing with Eli Lilly’s Zepbound.
Novo Nordisk executives overlooked warnings ahead of Wegovy’s launch, leading to supply issues, high costs, and challenges competing with Eli Lilly’s Zepbound.
The UCW Newswire : Financial, Business and Tech NewsCopyright © Louis Velazquez. All Rights Reserved.